Public Opinion on Prescription Drugs and Their Prices

This chart collection draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices, including the Inflation Reduction Act.

Read More

What is the Critical Medicines Act?

On Tuesday (11 March 2025) the European Commission presented the draft of its new Critical Medicines Act (CMA). The Science Media Centre España writes that the CMA’s objective is: …to address the serious shortage of medicines and healthcare products, reduce external dependence on critical medicines and ingredients — especially from Asia — and guarantee the…

Read More

BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers. The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.

Read More

Does American Health Care Violate the ICJ’s Recent Climate Advisory Opinion?

By DAVID INTROCASO In late July the UN International Court of Justice (ICJ) announced its long-awaited and highly-anticipated climate advisory opinion.  The ICJ ruling represents an historic moment in climate accountability. “Obligations of States in Respect of Climate Change” In a rare unanimous decision, the ICJ opinion concluded “a clean, healthy and sustainable environment” is in…

Read More

Proposed Medicaid Federal Match Penalty for States that Have Expanded Coverage for Immigrants: State-by-State Estimates

This analysis examines the potential impacts of a provision in the House reconciliation bill that proposes reducing the federal matching rate for the Affordable Care Act (ACA) Medicaid expansion population from 90% to 80% for states that either provide health coverage or financial assistance to purchase health coverage to individuals who are not “a qualified…

Read More

4 Things That Worry FDA Commissioner Robert Califf

This week at HLTH, FDA Commissioner Robert Califf discussed the current state of healthcare AI. He talked about some of the qualms he has, such as his worry that AI is worsening health inequities and his concern that providers aren’t capable of validating AI tools’ effectiveness. The post 4 Things That Worry FDA Commissioner Robert…

Read More